drugset / Trial / NCT02201420

Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT

NCT02201420

Phase 2 Completed 5 enrolled Navidea Biopharmaceuticals
NaSingle-groupOpen-labelDiagnostic

Summary

The purpose of this study (NAV3-12) is to determine the dissemination and localization of Tc 99m tilmanocept by SPECT and SPECT/CT imaging in subjects with confirmed cutaneous KS. This is a single center, open-label, within-subject study.

Timeline

Start
2014-09
Primary completion
2015-03
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Tilmanocept Diagnostic / imaging agent 50 ug
Subject Tilmanocept Diagnostic / imaging agent 74 mbq

Indications